文献速递乳腺癌放疗放疗物理与技术姑息放疗与转移瘤

再程放疗联合区域或电容式热疗用于既往照射区域乳腺复发癌的多模式治疗

Combined re-radiation therapy and regional or capacitive hyperthermia as a part of multimodal treatment for locoregional breast cancer recurrences in previously irradiated areas.
PubMed 文献 · Radiat Oncol · 2026-10-06

该回顾性分析纳入15例既往接受过放疗的局部区域乳腺复发癌患者共17个复发病灶,再程放疗中位剂量50 Gy并联合区域热疗或电容式热疗,中位随访30.1个月,估计2年无进展生存率75%,末次随访总生存率60%,仅见1–2级毒性且无≥3级毒性,提示该联合方案可行。

要点

  • 再程放疗中位剂量50 Gy联合热疗,中位热疗7次(范围1–24次,IQR 5.5–10)
  • 随访中位30.1个月,2年无进展生存率75%,末次随访总生存率60%
  • 急性和晚期毒性均限于1–2级,未观察到≥3级毒性

核心结论

  • 区域热疗或电容式热疗联合多模式治疗对既往照射区域的乳腺复发癌患者是可行的,并显示出令人鼓舞的初步临床结局。

研究设计与样本

  • 回顾性分析纳入既往接受过放疗的局部区域乳腺复发癌患者15例、共17个局部区域复发病灶。
  • 再程放疗与区域热疗或电容式热疗联合,并整合入个体化多模式治疗概念。
  • 热疗在放疗后即刻进行,每周1次或2次,区域热疗进行温度监测;主要终点为无进展生存期,次要终点为总生存期和毒性。

主要发现

  • 再程放疗中位剂量50 Gy,热疗中位7次(范围1–24次,四分位距5.5–10)。
  • 中位随访30.1个月(范围5–76个月,四分位距13–43),随访期间2例患者出现局部进展。
  • 估计2年无进展生存率为75%,末次随访时总生存率为60%。
  • 急性和晚期毒性均限于1–2级,未观察到≥3级毒性。

临床怎么用

  • 对于既往照射区域内的局部区域乳腺复发癌,可考虑将区域热疗或电容式热疗与再程放疗及个体化多模式治疗整合为挽救治疗策略。
  • 治疗中热疗可每周1次或2次于放疗后即刻进行,区域热疗需进行温度监测。

局限性

  • 本研究为回顾性分析,样本量小(15例患者、17个复发病灶),结果需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hyperthermia (HT) enhances the effects of radiotherapy (RT) and has shown benefit in recurrent breast cancer. Most existing studies focus on conventional superficial HT, whereas the efficacy of regional hyperthermia (RHT) and capacitive hyperthermia (CHT) in previously irradiated areas remains underexplored. METHODS: Patients with locoregional breast cancer recurrences previously treated with RT were included in this retrospective analysis. Re-irradiation was delivered in combination with RHT or CHT and was integrated into an individualized multimodal treatment concept. HT was applied once or twice weekly immediate following RT, with temperature monitoring performed for RHT. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and toxicity. RESULTS: A total of 15 patients with 17 locoregional recurrences were included. Patients received re-RT with a median dose of 50 Gy and a median of 7 HT sessions (range, 1-24 sessions; Interquartile range (IQR), 5.5-10). After a median follow-up of 30.1 months (range, 5-76 months; IQR, 13-43) two patients experienced local progression during follow-up. The estimated 2-year PFS was 75%, and OS was 60% at last follow-up. Acute and late toxicities were limited to grade 1-2 events, with no grade ≥ 3 toxicity observed. CONCLUSION: This retrospective analysis demonstrates the feasibility of combining RHT or CHT with multimodal treatment in patients with recurrent breast cancer and provides encouraging preliminary clinical outcomes. Despite the limitations, these findings support the integration of RHT and CHT into salvage treatment strategies and justify further prospective investigation. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kopp DH, Giovannelli AC, Mehrhof F, et al. Combined re-radiation therapy and regional or capacitive hyperthermia as a part of multimodal treatment for locoregional breast cancer recurrences in previously irradiated areas. Radiat Oncol. 2026. PMID: 42844618. doi:10.1186/s13014-026-02932-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。